Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
FRLN was delisted on the 16th of February, 2024.
11 hedge funds and large institutions have $5.09M invested in Freeline Therapeutics Holdings plc American Depositary Shares in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
27% less funds holding
Funds holding: 15 → 11 (-4)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
70% less capital invested
Capital invested by funds: $16.9M → $5.09M (-$11.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$394K |
| 2 |
Morgan Stanley
New York
|
+$87.7K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$61.8K |
| 4 |
Renaissance Technologies
New York
|
+$25.6K |
| 5 |
HCA
Harbor Capital Advisors
Chicago,
Illinois
|
+$13.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.16M |
| 2 |
CA
CHI Advisors
New York
|
-$1.16M |
| 3 |
Millennium Management
New York
|
-$75K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$53.7K |
| 5 |
Two Sigma Investments
New York
|
-$19.6K |
FRLN Hedge Fund Activity: Q2 2023 in Review
11 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Freeline Therapeutics Holdings plc American Depositary Shares (FRLN) for Q2 2023, worth a combined $5.09M — down 70% from $16.9M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of FRLN and 2 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $394K. The largest seller was Eventide Asset Management, exiting entirely with an estimated $2.16M sold.
- 11 institutional investors held Freeline Therapeutics Holdings plc American Depositary Shares (FRLN) as of Q2 2023, down from 15 in Q1 2023.
- Funds reported $5.09M of Freeline Therapeutics Holdings plc American Depositary Shares stock for Q2 2023, down 70% quarter-over-quarter.
- 2 funds opened new Freeline Therapeutics Holdings plc American Depositary Shares positions in Q2 2023 and 5 closed out, a net change of -3 holders.
- The largest Freeline Therapeutics Holdings plc American Depositary Shares buyer in Q2 2023 was Tang Capital Management, an estimated $394K added.
- The largest Freeline Therapeutics Holdings plc American Depositary Shares seller in Q2 2023 was Eventide Asset Management, an estimated $2.16M sold.
Based on aggregated 13F filings for Q2 2023.